Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K33/00—Medicinal preparations containing inorganic active ingredients
  • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
  • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
  • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
  • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
  • A61K36/18—Magnoliophyta (angiosperms)
  • A61K36/185—Magnoliopsida (dicotyledons)
  • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
  • A61K36/18—Magnoliophyta (angiosperms)
  • A61K36/185—Magnoliopsida (dicotyledons)
  • A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
  • A61K36/18—Magnoliophyta (angiosperms)
  • A61K36/88—Liliopsida (monocotyledons)
  • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
  • A61K36/8962—Allium, e.g. garden onion, leek, garlic or chives
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
  • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/02—Nutrients, e.g. vitamins, minerals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
  • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

• the present invention relates to nutritional or pharmaceutical compositions comprising extracts or concentrates of certain plants and their use as inhibitors of bone resorption.
• Osteoporosis can be generally defined as the reduction in the quantity of bone, either from the reduction in bone formation or the acceleration of bone resorption, in either event the result is a decrease in the amount of skeletal tissue.
• Osteoclasts bone resorbing cells
• Osteoclasts bone resorbing cells
• compositions and methods are described in the medical literature for the treatment of osteoporosis.
• estrogens, calcitonin and bisphosphonates are known to be effective inhibitors of bone resorption.
• the present invention relates to the use of a vegetable extract or concentrate, excluding extracts or concentrates derived from leguminosae and hop, having an inhibitory effect on bone resorption in the preparation of a medicament or nutritional formulation for the treatment or prophylaxis of a disease or condition which is characterized by increased bone resorption, such as Paget's disease, tumor-induced bone disease or particularly osteoporosis.
• leguminosae is meant the botanical family leguminosae (pea family) which includes for example soybean, beans, chick pea or lentil.
• hop is meant the botanical species Humulus lupulus.
• Osteoporosis as used herein includes osteoporosis induced by hormone deficiency (e.g. postmenopausal) and old age, as well as secondary osteoporosis such as osteoporosis secondary to steroid treatment or secondary to malnutrition caused by anorexia nervosa.
• hormone deficiency e.g. postmenopausal
• secondary osteoporosis such as osteoporosis secondary to steroid treatment or secondary to malnutrition caused by anorexia nervosa.
• the invention further provides a method for the treatment or prophylaxis of a disease or condition which is characterized by increased bone resorption, such as Paget's disease, tumor-induced bone disease or particularly osteoporosis, comprising the administration of a medicament or nutritional formulation to a human or other mammal, said medicament or nutritional formulation comprising a vegetable extract or concentrate, excluding extracts or concentrates derived from leguminosae and hop, in an amount which is effective for inhibiting bone resorption.
• a disease or condition which is characterized by increased bone resorption, such as Paget's disease, tumor-induced bone disease or particularly osteoporosis
• the present invention also foresees the use of an extract or concentrate from a plant selected from the group consisting of allium, petroselinum, brassica and eruca extracts and concentrates in the preparation of a medicament or nutritional formulation for the treatment or prophylaxis of a disease or condition which is characterized by increased bone resorption, such as Paget's disease, tumor-induced bone disease or particularly osteoporosis.
• a method for the treatment or prophylaxis of a disease or condition which is characterized by increased bone resorption comprising the administration of a medicament or nutritional formulation to a human or other mammal, said medicament or nutritional formulation comprising an extract or concentrate from a plant selected from the group consisting of allium, petroselinum, brassica and eruca extracts and concentrates, in an amount which is effective for inhibiting bone resorption.
• the extracts and concentrates from allium, petroselinum, brassica and/or eruca are vegetable extracts or concentrates.
• the term vegetable refers to a herbaceous plant which has an edible portion which is consumed by humans in either raw or cooked form.
• the edible portion may be a root, such as rutabaga, beet, carrot, and sweet potato; a tuber or storage stem, such as potato and taro; the stem, as in asparagus and kohlrabi; a bud, such as brussels sprouts; a bulb, such as onion and garlic; a petiole or leafstalk, such as celery and rhubarb; a leaf, such as cabbage, lettuce, parsley and spinach; an immature flower, such as cauliflower, broccoli and artichoke; a seed; the immature fruit, such as eggplant, cucumber, and sweet corn (maize); or the mature fruit, such as tomato and pepper.
• a root such as rutabaga, beet, carrot, and sweet potato
• a tuber or storage stem such as potato and taro
• the stem as in asparagus and kohlrabi
• a bud such as brussels sprouts
• a bulb such as onion and garlic
• a petiole or leafstalk
• allium refers to the genus allium (latin for garlic, a member of the onion family) and includes for example any member of the botanical species Allium cepa (onion), Allium ascalonicum (shallot), Allium ampeloprasum (leek/great-headed-garlic), Allium porrum (leek), Allium schoenoprasum (chive), Allium ursinum (bear's garlic), Allium sativum (garlic) or Allium fistulosum (bunching onion).
• Allium ascalonicum shallot
• Allium porrum leek
• Allium cepa onion
• Allium ursinum bear's garlic, also known as bear paw garlic
• members of the species Allium cepa are common onions (with red or white or yellow skins) or shallots, whereby red or white common onions are preferred.
• the onion extracts and concentrates are prepared e.g. from the whole eatable part of the vegetable.
• Suitable chive extracts and concentrates are obtained e.g. from chive herbs.
• Suitable bear's garlic extracts and concentrates are obtained e.g. from bear's garlic bulbs, fresh herbs or from the whole blooming plant, preferably they are obtained form fresh herbs.
• petroselinum refers to the genus petroselinum (common name parsley) and includes for example any member of the botanical species Petroselinum crispum. Examples are Petroselinum crispum crispum, that is common parsley with curly leaves, Petroselinum crispum radiosum or Petroselinum crispum var. neapolitanum also known as Italian Parsley with flat leaves. Suitable petroselinum extracts or concentrates may be produced e.g. from roots, fruits or seeds, or particularly from herbs.
• brassica refers to the genus brassica (latin for cabbage) and includes for example any member of the botanical species Brassica oleracea, Brassica napus, Brassica rapa, Brassica alboglabra, Brassica juncea, Brassica perviridis, Brassica alba and Brassica nigra.
• Brassica oleracea is a preferred species, particularly preferred members of this species are Brassica oleracea var. italica, i.e. broccoli, or Brassica oleracea var. gemmifem, i.e. Brussels sprouts.
• Broccoli extracts and concentrates are particularly preferred as brassica extract or concentrate. Suitable extracts and concentrates of brassica oleraceae species are produced advantageously from the whole eatable part of the vegetable or from the freshly germinated sprouts or shoots.
• eruca refers to the genus eruca and includes in particular any member of the botanical species Eruca sativa (wild form) or Eruca vesicaria subsp. sativa (cultivated form) for which the common name is arrugula or roquette.
• the plant/vegetable extracts and concentrates of the invention are preferably obtained from an edible portion of the plant or vegetable.
• edible portion is meant the portion which is consumed by humans in either raw or cooked form.
• a preferred group of inventive plant/vegetable extracts and concentrates comprises concentrates or extracts from any member of the botanical species Allium cepa, Allium ascalonicum, Allium ursinum, Petroselinum crispum, Brassica oleracea or Eruca sativa.
• a more preferred group of inventive plant/vegetable extracts and concentrates comprises extracts and concentrates from any member of the botanical species Allium cepa, Petroselinum crispum (in particular Petroselinum crispum crispum and Petroselinum crispum var. neapolitanum) and Brassica oleracea (in particular Brassica oleracea var.
• italica particularly extracts and concentrates of onions ⁇ Allium cepa), Italian Parsley (Petroselinum crispum var. neapolitanium) or broccoli (Brassica oleracea var. italica).
• onion extracts in particular white onion extracts
• the extracts and concentrates of the above-mentioned plants or vegetables may be in liquid form or in solid form such as in granulate or powder form.
• Suitable plant or vegetable concentrates are obtainable e.g. by drying or freeze-drying the fresh-cut plants or vegetables or the respective roots, fruits or seeds thereof and then optionally grinding or granulating the dried material; or by squeezing the fresh-cut plants or vegetables or the respective roots, fruits or seeds thereof and gathering the liquid fraction and optionally drying it.
• the use of a concentrate of the above-mentioned plants or vegetables in solid form and particularly in powder form is preferred.
• Suitable methods of obtaining extracts of the above-mentioned plants or vegetables are known in the art.
• the plant or vegetable extracts are obtainable e.g. by extracting the fresh- cut or dried plants or vegetables or the respective roots, fruits or seeds thereof for example with water or with one or more food grade solvents or with a mixture of water and one or more food grade solvents.
• Suitable food grade solvents include propane, butane, butyl acetate, ethyl acetate, ethanol, carbon dioxide, acetone, nitrous oxide, methanol and propan-2-ol, whereby ethanol and carbon dioxide are preferred; ethanol is a particularly preferred food grade solvent.
• the liquid phase is optionally concentrated or dried by evaporation or freeze drying.
• the fresh-cut or dried plant or vegetable material may be introduced in cold or preferably hot water and/or solvent, preferably water or a mixture of water with one or more solvents, for a specified period of time, which may vary within wide ranges depending on the kind of plant or vegetable material or solvent used but commonly amounts for example to 1 to 30 minutes, preferably 2 to 15 minutes and most preferred 5 to 10 minutes for a water extraction and for example 30 to 90 minutes, preferably 60 minutes for an ethanol/water extraction.
• the temperature preferably lies in the range of 85 to 95°C and for an alcohol/water extraction the temperature preferably lies in the range of 55 to 65°C.
• the extraction preferably takes place at 0 to 40°C and at supercritical pressure (e.g.
• the liquid phase is separated and advantageously concentrated or evaporated to dryness according to known methods.
• a concentrated extract two or more extraction steps as described above may be combined.
• the plant or vegetable extracts may be obtained by introducing the fresh-cut or dried plant or vegetable in water and subjecting the mixture to a steam distillation. The distillate is collected and is then advantageously concentrated or evaporated to dryness.
• the extract may be used in liquid form, particularly in aqueous form, or in solid form, particularly in granulate or powder form. If the extract is in liquid form, it has a solid contents of for example from 1 to 25 % by weight, preferably from 2 to 20 % by weight and most preferred from 2 to 15 % by weight.
• inventive plant/vegetable extract or concentrate to be supplied may vary within wide ranges, depending on i.a. the desired treatment, subject to be treated and his needs.
• a satisfactory inhibitory effect on bone resorption is, in general obtained with compositions formulated to allow a daily administration of 0.1 to 20 grams, preferably 0.2 to 15 grams and most preferred 0.4 to 10 grams of allium, petroselinum, brassica and/or eruca concentrate or extract (on a solvent-free basis).
• Suitable nutritional compositions comprising the above-mentioned plant/vegetable extracts or concentrates represent a further object of the invention. They are characterized in that they comprise
• At least one energy source selected from the group consisting of carbohydrate, fat and nitrogen sources, and optionally
• component (a) the definitions, preferences and amounts given before for the allium, petroselinum, brassica and eruca extracts and concentrates apply. It is also possible to have a mixture of two or more of said plant/vegetable extracts and concentrates as component (a).
• the nutritional compositions of the invention conveniently comprise (in % by weight) for example from approximately 0.1 to 40 %, preferably from approximately 3 to 25 % and most preferred from 5 to 15 % of plant/vegetable extract or concentrate component (a).
• the calcium source (b) may comprise any physiological acceptable inorganic or organic compound containing calcium.
• inorganic calcium salts for example calcium chloride, calcium phosphate, calcium sulfate, calcium oxide, calcium hydroxide or calcium carbonate, or organic calcium components like whole or skim milk powder, calcium caseinate or calcium salts of organic acids such as calcium citrate, calcium maleate, or mixtures thereof.
• organic calcium compounds particularly skim milk powder, calcium caseinate or mixtures thereof, as calcium source (b) is preferred.
• the amount of calcium component to be supplied may vary within wide ranges.
• the inventive compositions comprise in one unit dosage from about 100 mg to 1000 mg, preferably 200 mg to 700 mg and most preferred 300 to 600 mg of calcium (on an elemental basis).
• the nutritional compositions of the invention conveniently comprise (in % by weight) for example from approximately 1 to 60 %, preferably from approximately 5 to 50 % and most preferred from 10 to 40 % of calcium component (b).
• Suitable carbohydrate sources include for example maltodextrins, starch, lactose, glucose, sucrose, fructose, xylit and/or sorbit. In these forms the carbohydrates are both energy suppliers and sweeteners.
• the inventive compositions may contain one or more different carbohydrate sources.
• Suitable fat sources include omega-6 polyunsaturated fatty acid sources, omega-3 polyunsaturated fatty acid sources, mono-unsaturated fatty acid sources, medium chain fatty acid sources (i.e. C 6 -C ⁇ 2 -fatty acids); or mixtures thereof.
• the above-mentioned fatty acids may be employed in each case in form of the free acid, in mono-, di- or particularly in triglyceride form, or in form of a pharmacological or nutritional acceptable natural source.
• Suitable natural sources of omega-6 polyunsaturated fatty acids include vegetable oils such as safflower oil, sunflower oil, soya oil, cotton oil and corn oil.
• Suitable natural sources of omega-3 polyunsaturated fatty acids include linseed oil and fish oils such as menhaden oil, salmon oil, mackerel oil, tuna oil codliver oil and anchovy oil.
• Suitable natural sources of mono-unsaturated fatty acid sources are particularly omega-9 mono-unsaturated fatty acids, for example olives, canola, safflower (hybrids) and sunflower (hybrids).
• a preferred fat source comprises triglyceride oils supplying the desired amounts of omega-6 polyunsaturated fatty acids and omega-3 polyunsaturated fatty acids and which are rich in the medium chain fatty acid residues (i.e. residues of C 6 -C ⁇ 2 fatty acid) and/or mono- unsaturated fatty acid residues.
• the inventive compositions may contain one or more different fat sources.
• suitable nitrogen sources of the inventive nutritional compositions include sources containing nutritionally acceptable proteins such as soy bean derived proteins; milk proteins such as whey proteins or caseinates; and/or protein hydrolysates; and/or essential amino acids mixtures in free amino acid form or salt form; and/or compounds associated with the synthesis of polyamines, such as arginine, arginine precursors, ornithine and the like, in free amino acid form or salt form.
• Preferred nitrogen sources of the nutritional compositions are:
• soy bean derived proteins which may be employed in the form of soy beans or in the form of any suitable soja extract or concentrate, for example in form of soy flour, dried soy sprouts, soybean milk, or as dried aqueous extract from soybeans; or
• milk proteins for example whey derived proteins or caseinates which may be employed for example in the form of whey powder, caseinate salts such as calcium caseinate and/or whole or preferably skim milk powder and/or
• Milk proteins such as whey powder, caseinates, particularly calcium caseinate, and/or skim milk powder are another particularly preferred nitrogen source of the claimed nutritional compositions.
• the inventive compositions may contain one or more different nitrogen sources.
• the nutritional compositions comprise (in % by weight) for example, from approximately 0.1 % to 98,9 %, preferably from approximately 1 to approximately 95 %, and most preferred from 10 to 90 % of energy source component (c).
• the carbohydrate source provides for 30 to 70 % of the total energy supply, the nitrogen source for 5 to 45% and the fat source for 0. 1 to 15 % of the total energy supply of the composition.
• the carbohydrate source provides for 40 to 60 % of the total energy supply, the nitrogen for 20 to 35 % and the fat source for 3 to 12 % of the total energy supply of the composition.
• a preferred energy source (c) of the inventive compositions comprises
• carbohydrate sources selected from the group consisting of maltodextrins, starch, lactose, glucose, sucrose, fructose, xylit and sorbit;
• a particularly preferred energy source (c) of the inventive compositions comprises
• carbohydrate sources selected from the group consisting of maltodextrins, starch, lactose, glucose, sucrose, fructose, xylit and sorbit;
• the amount of Vitamin D (optional component (d)) to be supplied may vary within wide ranges.
• the inventive compositions comprise in one unit dosage from about 400 IU to 1000 IU, preferably about 500 IU.
• the nutritional formulations of the invention may comprise other nutritionally acceptable components such as vitamins, minerals, trace elements, fibers (preferably soluble fibers), flavors, preservatives, colorants, sweeteners, emulsifiers and the like.
• vitamins suitable for the incorporation in the composition of the invention include Vitamin A, Vitamin D, Vitamin E, Vitamin K, Vitamin C, folic acid, thiamin, riboflavin, Vitamin B 6 , Vitamin B 12 , niacin, biotin and panthotenic acid in pharmaceutical or nutritionally acceptable form.
• mineral elements and trace elements suitable for the incorporation in the composition of the invention include sodium, potassium, phosphorous, magnesium, copper, zinc, iron, selenium, chromium and molybdenum in pharmaceutical or nutritionally acceptable form.
• soluble fiber refers to fibers which are able to substantially undergo fermentation in the colon to produce short chain fatty acids.
• suitable soluble fibers include agar-agar, alginates, carubin, carrageenan, gum arabic, guar gum, karaya gum, locust bean gum, pectin, tragacanth, or xanthan gum. They may be hydrolysed or not.
• Suitable flavors include natural or artificial flavors, for example fruit flavors such as banana, orange, peach, pineapple or rasberry; vegetable flavors; or vanilla, cocoa, chocolate, coffee and the like.
• Preferred ingredients of the inventive nutritious compositions in addition to components (a), (b), (c) and (d) comprise beta-carotene (Vitamin A), Vitamin E, Vitamin C, thiamin, Vitamin B B 6 and/or B 12 , potassium, magnesium, selenium, zinc, phosphorous and soluble fiber in pharmaceutical or nutritionally acceptable form.
• the nutritional compositions may comprise (in % by weight) for example, from approximately 0.1 % to 15 %, preferably from approximately 0.2 to approximately 10 %, and most preferred from 0.5 to 5 % of these additional components other than components (a), (b), (c) and optionally (d).
• the inventive nutritional formulations may be formulated and administered in any form suitable for enteral administration, for example oral administration or tube feeding, e.g. nasal administration.
• the formulations are conveniently administered in the form of an aqueous liquid.
• the formulations suitable for enteral application are accordingly preferably in aqueous form or in powder or granulate form, whereby the powder or granulate is conveniently added to water prior to use.
• the amount of water to be added will i.a. depend on the patient's fluid requirements and condition.
• the inventive nutritional compositions may be in form of a complete formula diet (in liquid or powder form), such that, when used as sole nutrition source essentially all daily caloric, nitrogen, fatty acids, vitamin, mineral and trace element requirements are met.
• the daily amount to be supplied to adult persons will lie in the range of 750 to 3500 kcal/day, in particular of 1000 to 2000 kcal/day.
• the inventive nutritional compositions are preferably intended for use as a dietary supplement.
• the amount of energy supplied by a supplement should not be too excessive, in order not to unnecessarily suppress the patients appetite.
• the supplement conveniently comprises energy sources in an amount supplying from 50 to 1500 kcal/day, preferably 100 to 900 kcal/day and most preferred 150 to 700 kcal/day.
• the nutritional compositions of the invention which are in liquid form, for example in drink form, or preferably in solid form, for example in granulate or powder form, may be obtained in a manner known per se, e.g. by admixing the ingredients and optionally adding water.
• the invention further relates to pharmaceutical compositions in single dose unit form comprising
• compositions for enteral administration such as oral, nasal or rectal administration.
• Suitable pharmaceutical compositions may be in liquid form or preferably in solid form and comprise (in % by weight) for example, from approximately 0.001 % to 100 %, preferably from approximately 0.1 to approximately 50 %, active ingredient (a).
• the active ingredient (a) is a plant/vegetable extract or concentrate selected from the group consisting of allium, petroselinum, brassica and eruca extracts and concentrates where the above-given definitions and preferences apply. It is also possible to have a mixture of two or more of said plant/vegetable extracts and concentrates a).
• compositions for enteral administration are, for example, those in single dose unit forms, such as dragees, tablets, capsules or sachets. They are prepared in a manner known perse, for example by means of conventional mixing, granulating, confectioning, dissolving or lyophilising processes.
• compositions for oral administration can be obtained by combining the active ingredient with solid carriers, optionally granulating a resulting mixture and processing the mixture or granules, if desired or necessary after the addition of suitable excipients, to form tablets or dragee cores.
• Suitable carriers are especially fillers, such as sugars, for example lactose, saccharose, mannitol or sorbitol, cellulose preparations and/or calcium phosphates, for example tri- calcium phosphate or calcium hydrogen phosphate, and also binders, such as starch pastes using, for example, corn, wheat, rice or potato starch, gelatin, tragacanth, methylcellulose and/or polyvinylpyrrolidone, and, if desired, disintegrators, such as the above-mentioned starches, and also carboxymethyl starch, cross-linked polyvinylpyrrolidone, agar, or alginic acid or a salt thereof, such as sodium alginate.
• fillers such as sugars, for example lactose, saccharose, mannitol or sorbitol, cellulose preparations and/or calcium phosphates, for example tri- calcium phosphate or calcium hydrogen phosphate
• binders such as starch pastes using,
• Excipients are especially flow-conditioners and lubricants, for example silicic acid, talc, stearic acid or salts thereof, such as magnesium or calcium stearate, and/or polyethylene glycol.
• Dragee cores are provided with suitable, optionally enteric, coatings, there being used inter alia concentrated sugar solutions which may contain gum arabic, talc, polyvinylpyrrolidone, polyethylene glycol and/or titanium dioxide, or coating solutions in suitable organic solvents or solvent mixtures or, for the preparation of enteric coatings, solutions of suitable cellulose preparations, such as acetylcellulose phthalate or hydroxypropylmethylcellulose phthalate.
• Dyes or pigments may be added to the tablets or dragee coatings, for example for identification purposes or to indicate different doses of active ingredient.
• Other orally administrable pharmaceutical compositions are hard gelatin capsules and also soft, sealed capsules consisting of gelatin and a plasticiser, such as glycerol or sorbitol.
• the hard gelatin capsules may comprise the active ingredient in the form of granules, for example in admixture with fillers, such as lactose, binders, such as starches, and/or glidants, such as talc or magnesium stearate, and, if desired, stabilisers.
• the active ingredient is preferably dissolved or suspended in suitable liquids, such as fatty oils, paraffin oil or liquid polyethylene glycols, it is likewise being possible to add stabilisers.
• Suitable rectally administrable pharmaceutical compositions are, for example, suppositories that consist of a combination of the active ingredient with a suppository base material.
• Suitable suppository base materials are, for example, natural or synthetic triglycerides, paraffin hydrocarbons, polyethylen glycols or higher alkanols. It is also possible to use gelatin rectal capsules which comprise a combination of the active ingredient with a base material.
• Suitable base materials are, for example, liquid triglycerides, polyethylenglycols or paraffin hydrocarbons.
• the inhibitory effect on bone resorption of the inventive plant or vegetable extracts and concentrates may be assessed by measuring the urinary excretion of [ 3 H]-tetracycline from chronically prelabled rats as described in R.C. M ⁇ hlbauer and H. Fleisch, Am J Physiol 258, R 679-R689 (1990).
• the method is based on the characteristics (i) that 3 H-labeled tetracycline is deposited in hard tissues during their formation; and (ii) when bone is resorbed, [ 3 H]-tetracycline is released, circulates in blood, and is excreted into the urine where it can be assessed by counting 3 H.
• the method may be performed as follows; rats are injected subcutaneously twice a week with increasing volumes of a solution containing [ 3 H]-tetracycline starting shortly after birth until the age of about six weeks. At the age of about 50 days, the animals are transferred to individual metabolic cages and every rat is fed with the same amount of a standardized diet for about the three weeks.
• one group of rats is fed with a purified diet, and another group is fed with the purified diet containing in addition a certain amount of an inventive plant or vegetable concentrate or extract.
• the animals have free access to demineralized water.
• the rats are about 60 days old, daily 24-hour urine collections are started, and the 3 H contents in urine are determined by liquid scintillation counting.
• a diagram is then prepared wherein the [ 3 H]-tetracycline contents in urine of the two groups of rats are plotted as a function of time (days).
• the plant or vegetable extracts and concentrates of the invention are capable of considerably decreasing the cumulative [ 3 H]-tetracycline excretion in urine of intact males and castrated female rats which indicates a high inhibitory effect on bone resorption. Accordingly, the claimed nutritional and pharmaceutical compositions are useful for the treatment and prophylaxis of all kinds of diseases or conditions which are characterized by increased bone resorption, such as Paget's disease, tumor-induced bone disease or particularly osteoporosis.
• the inhibitory effect of the plant or vegetable extracts or concentrates on bone resorption may also be assessed by an in vitro assay (described in Example 3) in which ivory slices, onto which freshly isolated osteoclasts have been settled, are incubated with a medium containing the extract or concentrate to be tested.
• the inhibitory effect on osteoclasts is assessed by counting the osteoclast resorption pits on the ivory slice.
• Inventive Extract/Concentrate 1 14.5 g including carbohydrates, protein and fiber
• Carbohydrates (including inventive extract) 31.0 g including - lactose 16.5 g
• vitamin A 0.3 mg -Calciferol (vitamin D) 5.0 meg -Tocopherol (vitamin E) 3.0 mg -Phylioquinone (vitamin K1 ) 30.0 meg -Thiamin (vitamin B1 ) 0.4 mg -Riboflavin (vitamin B1) 0.5 mg -Pyridoxine (vitamin B6) 0.8 mg -Cyanocobalamin (vitamin B12) 0.8 meg -Ascorbic acid (vitamin C) 20.0 mg -Biotin 50.0 meg -Folic acid 120.0 meg -Niacinamide 5.0 mg -Panthothenic acid 2.0 mg
• Extract 1 obtained by extracting 48.3 g dry broccoli for 10 minutes at 89 ⁇ 3°C with 483 ml distilled water and then evaporating the extract to dryness.
• Extract 2 obtained by extracting 48.3 g dry Italian Parsley for 10 minutes at 89 ⁇ 3°C with 483 ml distilled water and then evaporating the extract to dryness.
• Extract 3 obtained by extracting 26.4 g dry onions for 10 minutes at 89 ⁇ 3°C with 264 ml distilled water and then evaporating the extract to dryness .
• Extract 4 obtained by extracting 58.9 g dry onions for 10 minutes at 89 ⁇ 3°C with 589 ml distilled water and then evaporating the extract to dryness, followed by a second extraction of the dried water extract with 324 ml of 85% ethanol/15% water for one hour at 60°C, cooling to room temperature and keeping over night at -20°C, decanting the supernatant, evaporating the alcohol and freeze-drying the extract.
• Extract 5 obtained by extracting 45.3 g dry onions for one hour at 60°C with 453 ml of 85% ethanol/15% water, filtrating, evaporating the alcohol and freeze-drying the extract.
• the above supplement may be mixed with water and taken in appropriate concentration between meals.
• Example 2 - Effect of H 2 0 extracts of broccoli, dog-parsley and onion on bone resorption
• the effect of the inventive plant or vegetable extracts and concentrates on bone resorption is based on a method as described in R.C. Muhlbauer and H. Fleisch, Am J Physiol 259, R 679-R689 (1990). Bone resorption is monitored by the urinary excretion of 3 H in Wistar rats prelabled from birth for 6 weeks with [ 3 H]-tetracycline as described in the above-mentioned reference. The rats are then housed in individual metabolic cages and are fed for 10 days with a standard laboratory chow (Kliba 331 , Klingentalm ⁇ hle, Kaiseraugst, Switzerland) containing 1.0 g Ca, 0.7 g P, and 80 IU of vitamin D3/IOO g of food.
• the rats are allocated to the different treatment groups. Using the baseline 24 hour [ 3 H]- tetracycline excretion as selection criterion, special care is taken to obtain similar mean initial values for each group. Thereafter, the rats are switched to the purified diet with or without inventive extract and daily 24-hour urine collections are performed over a period of 14 days, and the cumulative [ 3 H]-tetracycline excretion in urine is determined by liquid scintillation counting.
• Example 3 Effect of a bear's garlic concentrate on bone resorption
• Example 4 Effect of onion extract on in vitro resorption
• osteoclast-mediated resorption as described in Arnett TR, Spowage M, 1996, Modulation of the resorptive activity of rat osteclasts by small changes in extracellular pH near the physiological range. Bone 18:277-279) with the following modifications: instead of using bone wafers, ivory slices are used as mineral substrate to assess osteoclast resorption pits which are counted under tangential illumination after gold spottering (Vitte C, Fleisch H, Guenther HL, 1996, Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption, Endocrinology 137:2324-2333).
• one 4x4 millimeter ivory slice, onto which freshly isolated osteoclasts have been settled is incubated per well of a 48-well plate in 250 ⁇ l of a medium containing the extract to be tested during 24 hours at 37°C in a 5% CO 2 /air atmosphere.
• 8 slices are used for each dose 8 slices.
• Osteoclasts are harvested from femurs of newborn rats which are, after removing the cartilagenous ends, split in half and chopped transversally. This procedure leads to a cell suspension rich in other cells such as osteoblasts. This permits to test effects in broad conditions, that is, as to both, direct effect on osteoclast and indirect effect on the osteoclast mediated by other cells such as osteoblasts.
• the onion extract is obtained by extracting a fine powder of onion for 10 minutes in distilled water (100g/l) at 90°C, filtrating and freeze-drying the filtrate, followed by a second extraction of the dry water extract for one hour at 60°C in 85% ethanol/15% water, cooling to room temperature, keeping over night at -20°C to allow precipitation of unwanted material, decanting the supernatant, evaporating the alcohol and freeze-drying the thus obtained residue, whereby 250 mg f reeze-dried onion extract are obtained for each g of dry whole onion.
• the onion extract (0.017, 0.17, 1.7 mg onion extract/ml medium) inhibited osteoclast- mediated resorption of dentine in a dose-dependent manner, while the number of tartrate- resistant alcaline phosphatase positive (TRAP + ) multinucleated cells (MNC) did not decrease significantly. Thus, the ratio pits/ TRAP + MNC decreased significantly (p ⁇ 0.001 ). From this it is concluded that the presence of large numbers of TRAP + MNC in these cultures despite the additions of onion extract indicate that onion extract is not toxic to these cells but rather inhibits the activity of osteoclasts.
• TRAP + tartrate- resistant alcaline phosphatase positive multinucleated cells

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Natural Medicines & Medicinal Plants (AREA)
• Chemical & Material Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Engineering & Computer Science (AREA)
• Epidemiology (AREA)
• Botany (AREA)
• Mycology (AREA)
• Physical Education & Sports Medicine (AREA)
• Biotechnology (AREA)
• Microbiology (AREA)
• Medical Informatics (AREA)
• Alternative & Traditional Medicine (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Rheumatology (AREA)
• Orthopedic Medicine & Surgery (AREA)
• Nutrition Science (AREA)
• Inorganic Chemistry (AREA)
• Polymers & Plastics (AREA)
• Food Science & Technology (AREA)
• Hematology (AREA)
• Diabetes (AREA)
• Obesity (AREA)
• Medicines Containing Plant Substances (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Coloring Foods And Improving Nutritive Qualities (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Micro-Organisms Or Cultivation Processes Thereof (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Medicinal Preparation (AREA)

Priority Applications (13)

Applications Claiming Priority (2)

Publications (1)

Family

ID=10811813

Family Applications (1)

Country Status (23)

Cited By (7)

Families Citing this family (34)

Citations (2)

Family Cites Families (37)

• 1997
  • 1997-05-06 GB GBGB9709082.3A patent/GB9709082D0/en active Pending
• 1998
  • 1998-04-04 TW TW087105130A patent/TWI225403B/zh not_active IP Right Cessation
  • 1998-04-17 MY MYPI98001715A patent/MY123891A/en unknown
  • 1998-05-04 EP EP98925529A patent/EP0980250B1/en not_active Expired - Lifetime
  • 1998-05-04 DE DE69802522T patent/DE69802522T2/de not_active Expired - Lifetime
  • 1998-05-04 CZ CZ0392099A patent/CZ299766B6/cs not_active IP Right Cessation
  • 1998-05-04 JP JP54772998A patent/JP4447661B2/ja not_active Expired - Lifetime
  • 1998-05-04 ES ES98925529T patent/ES2167899T3/es not_active Expired - Lifetime
  • 1998-05-04 AU AU77616/98A patent/AU721339B2/en not_active Expired
  • 1998-05-04 CA CA2286614A patent/CA2286614C/en not_active Expired - Lifetime
  • 1998-05-04 CN CNB2005101141953A patent/CN100417394C/zh not_active Expired - Lifetime
  • 1998-05-04 ID IDW991298A patent/ID23496A/id unknown
  • 1998-05-04 IL IL13215998A patent/IL132159A/xx not_active IP Right Cessation
  • 1998-05-04 WO PCT/EP1998/002627 patent/WO1998050054A1/en not_active Ceased
  • 1998-05-04 RU RU99125337/14A patent/RU2196601C2/ru active
  • 1998-05-04 PL PL98336076A patent/PL190370B1/pl unknown
  • 1998-05-04 AR ARP980102070A patent/AR012653A1/es active IP Right Grant
  • 1998-05-04 CN CNA2008101096078A patent/CN101301329A/zh active Pending
  • 1998-05-04 CN CN98804812A patent/CN1101695C/zh not_active Expired - Lifetime
  • 1998-05-04 DK DK98925529T patent/DK0980250T3/da active
  • 1998-05-04 US US09/423,245 patent/US6638540B2/en not_active Expired - Lifetime
  • 1998-05-04 AT AT98925529T patent/ATE208625T1/de active
  • 1998-05-04 HU HU0002971A patent/HU230578B1/hu unknown
  • 1998-05-04 BR BRPI9808748A patent/BRPI9808748B1/pt not_active IP Right Cessation
  • 1998-05-05 ZA ZA983764A patent/ZA983764B/xx unknown
• 2002
  • 2002-01-10 CN CN021015813A patent/CN1366991B/zh not_active Expired - Lifetime

Patent Citations (2)

Non-Patent Citations (2)

Also Published As

Similar Documents

Legal Events